A protocol for the management of canine cerebrospinal fluid for the proteomic assessment of putative biomarkers

Veterinary Journal

Volumn 197, Issue 3, 2013, Pages 836-841

  Shafie, Intan N F ^a,b   Anderson, Thomas J ^a   Penderis, Jacques ^a   Eckersall, Peter D ^c   McLaughlin, Mark ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Biomarker; Canine; CSF; Protein stability; Sample handling

Indexed keywords

APOLIPOPROTEIN; CLUSTERIN; CYSTATIN C; HAPTOGLOBIN; PREALBUMIN;

ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOG; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN STABILITY; PROTEOMICS; ROOM TEMPERATURE; WESTERN BLOTTING;

ANIMALIA;

BIOMARKER; CANINE; CSF; PROTEIN STABILITY; SAMPLE HANDLING;

ANIMALS; BIOLOGICAL MARKERS; DOG DISEASES; DOGS; PROTEOMICS; SPECIMEN HANDLING;

EID: 84884977027     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.05.039     Document Type: Article

References (32)

1. Akerstedt M., Forsback L., Larsen T., Svennersten-Sjaunja K. Natural variation in biomarkers indicating mastitis in healthy cows. Journal of Dairy Research 2011, 78:88-96.
2. Aronson J.K. Biomarkers and surrogate endpoints. British Journal of Clinical Pharmacology 2005, 59:491-494.
3. Biroccio A., Del B.P., Panella M., Bernardini S., Di I.C., Gambi D., Stanzione P., Sacchetta P., Bernardi G., Martorana A., et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. Proteomics 2006, 6:2305-2313.
4. Boccio P.D., Pieragostinoa D., Lugaresi A., Ioia M.D., Pavone B., Travaglini D., D'Aguanno S., Sacchetta P., Federici G., Ilio, et al. Cleavage of cystatin C is not associated with multiple sclerosis. Annals of Neurology 2006, 62:201-204.
5. Braund K.G. Degenerative Disorders of the Central Nervous System 2003, International Veterinary Information Service, New York, USA,
6. Carrette O., Burkhard P.R., Hughes S., Hochstrasser D.F., Sanchez J. Truncated cystatin C in cerebrospinal fluid: Technical artefact or biological process?. Proteomics 2005, 5:3060-3065.
7. Del B.P., Pieragostino D., Lugaresi A., Di I.M., Pavone B., Travaglini D., D'Aguanno S., Bernardini S., Sacchetta P., Federici G., et al. Cleavage of cystatin C is not associated with multiple sclerosis. Annals of Neurology 2007, 62:201-204.
8. Ferguson R.E., Hochstrasser D.F., Banks R.E. Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomic Clinical Application 2007, 1:739-746.
9. Finehout E.J., Franck Z., Choe L.H., Relkin N., Lee K.H. Cerebrospinal fluid proteomic biomarker for Alzheimer's disease. Annals of Neurology 2007, 61:120-129.
10. Fry M.M., Vernau W., Kass P.H., Vernau K.M. Effects of time, initial composition, and stabilizing agents on the results of canine cerebrospinal fluid analysis. Veterinary Clinical Pathology 2006, 35:72-77.
11. Gutierrez A.M., Martinez-Subiela S., Ceron J.J. Evaluation of changes in haptoglobin and C-reactive protein concentrations caused by freezing of saliva and meat juice samples collected from healthy and diseased pigs. American Journal of Veterinary Research 2011, 72:11-17.
12. Herget-Rosenthal S., Feldkamp T., Volbracht L., Kribben A. Measurement of urinary cystatin C by particle-enhanced nephlometric immunoassay: Precision, interferences, stability and reference range. Annals of Clinical Biochemistry 2004, 41:111-118.
13. Hesse C., Larsson H., Fredman P., Minthon L., Andreasen N., Davidsson P., Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochemical Research 2000, 25:511-517.
14. Kaiser E., Schonknecht P., Thomann P.A., Hunt A., Schroder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neuroscience Letters 2007, 417:193-195.
15. Lamy E., da C.G., Santos R., Capela e Silva, Potes J., Pereira A., Coelho A.V., Sales B.E. Sheep and goat saliva proteome analysis: A useful tool for ingestive behavior research?. Physiology and Behaviour 2009, 98:393-401.
16. Maarouf C.L., Beach T.G., Adler C.H., Shill H.A., Sabbagh M.N., Wu T., Walker D.G., Kokjohn T.A., Roher A.E. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurology Research 2012, 34:669-676.
17. Mayeux R. Biomarkers: Potential use and limitations. The Journal of the American Society for Experimental NeuroTherapeutics 2004, 1:182-188.
18. Mitchell G.B., Clark M.E., Caswell J.L. Alterations in the bovine bronchoalveolar lavage proteome induced by dexamethasone. Veterinary Immunology and Immunopathology 2007, 118:283-293.
19. Moore R.E., Kirwan J., Doherty M.K., Whitfield P.D. Biomarker discovery in animal health and disease: The application of post-genomic technologies. Biomarker Insights 2007, 2:185-196.
20. Pasinetti G.M., Ungar L.H., Lange D.J., Yemul S., Deng H., Yuan X., Brown R.H., Cudkowicz M.E., Newhall K., Peskind E., et al. Identification of potential CSF biomarkers in ALS. Journal of Neurology 2006, 66:1218-1222.
21. Pieragostinoa D., Petruccia F., Boccioa P.D., Mantinia D., Lugaresia A., Tiberioa S., Onofrja M., Gambia D., Sacchettaa P., Ilioa C.D., et al. Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. Journal of Proteomics 2010, 73:579-592.
22. Ranganathan S., Polshyna A., Nicholl G., Lyons-Weiler J., Bowser R. Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clinical Proteomics 2006, 2:91-101.
23. Ranganathan S., Williams E., Ganchev P., Gopalakrishnan V., Lacomis D., Urbinelli L., Newhall K., Cudkowicz M.E., Brown R.H., Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Journal of Neurochemistry 2005, 95:1461-1471.
24. Redondo C., Damas A.M., Saraiva M.J. Designing transthyretin mutants affecting tetrameric structure: Implications in amyloidogenicity. Biochemical Journal 2000, 348:167-172.
25. Sanchez J., Guillaume E., Lescuyer P., Allard L., Carrette O., Scherl A., Burgess J., Corthals G.L., Burkhard P.R., Hochstrasser D.F. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4:2229-2233.
26. Serot J.M., Christmann D., Dubost T., Couturier M. Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 1997, 63:506-508.
27. Shao C., Li M., Li X., Wei L., Zhu L., Yang F., Jia L., Mu Y., Wang J., Guo Z., et al. A tool for biomarker discovery in the urinary proteome: A manually curated human and animal urine protein biomarker database. Molecular and Cellular Proteomics 2011, 10:111-118.
28. Sihlbom C., Davidsson P., Sjogren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochemical Research 2008, 33:1332-1340.
29. Talamo F., D'Ambrosio C., Arena S., Del V.P., Ledda L., Zehender G., Ferrara L., Scaloni A. Proteins from bovine tissues and biological fluids: Defining a reference electrophoresis map for liver, kidney, muscle, plasma and red blood cells. Proteomics 2003, 3:440-460.
30. Van Dijk K.D., Teunissen C.E., Drukarch B., Jimenez C.R., Groenewegen H.J., Berendse H.W., Van de Berg W.D.J. Diagnostic cerebral fluid biomarkers for Parkinson's disease: A pathogenetically based approach. Neurobiology of Disease 2010, 39:229-241.
31. Wait R., Miller I., Eberini I., Cairoli F., Veronesi C., Battocchio M., Gemeiner M., Gianazza E. Strategies for proteomics with incompletely characterized genomes: The proteome of Bos taurus serum. Electrophoresis 2002, 23:3418-3427.
32. Yool D.A., Klugmann M., McLaughlin M., Vouyiouklis D.A., Dimou L., Barrie J.A., McCulloch M.C., Nave K.A., Griffiths I.R. Myelin proteolipid proteins promote the interaction of oligodendrocytes and axons. Journal of Neuroscience Research 2001, 63:151-164.